| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay away. Here's why.
Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor was involved with and the po...
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by ...
https://www.zacks.com/stock/news/2589077/prokidney-cp-prok-upgraded-to-strong-buy-what-does-it-mean-for-the-stock
UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $4 to $8.
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD ...
-SEC Filing
